Filtered By:
Source: The Journal of Clinical Endocrinology and Metabolism
Condition: Diabetes
This page shows you your search results in order of date.
Order by Relevance | Date
Total 68 results found since Jan 2013.
Higher Risk of Incident Hyperthyroidism in Patients With Atrial Fibrillation
CONCLUSIONS: Our results provide insight into clinical risk factors for the development of hyperthyroidism in AF patients, as identified by the novel SAD HEC2 score. AF appears to be a common precursor of hyperthyroidism.PMID:37565329 | DOI:10.1210/clinem/dgad448
Source: The Journal of Clinical Endocrinology and Metabolism - August 11, 2023 Category: Endocrinology Authors: Pang-Shuo Huang Jen-Fang Cheng Jien-Jiun Chen Yi-Chih Wang Juey-Jen Hwang Cho-Kai Wu Chia-Ti Tsai Source Type: research
Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
J Clin Endocrinol Metab. 2023 Jul 6:dgad398. doi: 10.1210/clinem/dgad398. Online ahead of print.ABSTRACTGlucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RA may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across patient's risk with a particular focus in HF. After a careful review of the literature, we challenge the c...
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2023 Category: Endocrinology Authors: Jo ão Pedro Ferreira Abhinav Sharma Javed Butler Milton Packer Faiez Zannad Francisco Vasques-N óvoa Adelino Leite-Moreira Jo ão Sérgio Neves Source Type: research
Metabolic syndrome and C reactive protein are associated with a reduced myocardial mechano-energetic efficiency
CONCLUSION: Non-diabetic and prediabetic individuals with metabolic syndrome exhibit increased stroke work and myocardial oxygen consumption, and an impaired MEEi, an established predictor of adverse cardiovascular events, and elevated hsCRP levels in combination with metabolic syndrome aggravates the myocardial MEEi impairment.PMID:37235788 | DOI:10.1210/clinem/dgad300
Source: The Journal of Clinical Endocrinology and Metabolism - May 26, 2023 Category: Endocrinology Authors: Chiara M A Cefalo Alessia Riccio Teresa Vanessa Fiorentino Elena Succurro Sofia Miceli Gaia Chiara Mannino Maria Perticone Angela Sciacqua Francesco Andreozzi Giorgio Sesti Source Type: research
Cardio-cerebrovascular Outcomes in MODY, Type 1 Diabetes, and Type 2 Diabetes: A Prospective Cohort Study
CONCLUSIONS: MODY diagnosed by genetic analysis represents higher prevalence than the clinical diagnosis in UK Biobank. The risk of incident cardio-cerebrovascular events in MODY ranks between type 1 diabetes and type 2 diabetes.PMID:37093977 | DOI:10.1210/clinem/dgad233
Source: The Journal of Clinical Endocrinology and Metabolism - April 24, 2023 Category: Endocrinology Authors: Hui-Xuan Wu Tian-Yao Chu Junaid Iqbal Hong-Li Jiang Long Li Yan-Xuan Wu Hou-De Zhou Source Type: research
SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes
J Clin Endocrinol Metab. 2023 Feb 28:dgad113. doi: 10.1210/clinem/dgad113. Online ahead of print.ABSTRACTBACKGROUND: SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3P MACE), predominantly by reducing cardiovascular death. However reduction of the individual components, myocardial infarction (MI) or stroke (fatal and non-fatal) events have not been well explored.METHODS: In this meta-analysis, we included data avail...
Source: The Journal of Clinical Endocrinology and Metabolism - March 1, 2023 Category: Endocrinology Authors: Pradip Mukhopadhyay Debmalya Sanyal Purushottam Chatterjee Kaushik Pandit Sujoy Ghosh Source Type: research
GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.PMID:36800286 | DOI:10.1210/clinem/dgad076
Source: The Journal of Clinical Endocrinology and Metabolism - February 17, 2023 Category: Endocrinology Authors: Mainak Banerjee Rimesh Pal Satinath Mukhopadhyay Kirthana Nair Source Type: research
